Gilead Sciences is all set for its next big launch. On Wednesday, a day after the company reported a disappointing hepatitis C sales outlook, the drugmaker got a needed boost with the FDA's approval for HIV combo drug Biktarvy—a product some analysts see climbing to $10 billion.Original Article
Gilead’s Biktarvy wins megablockbuster HIV nod, and rival GlaxoSmithKline strikes back
